The Strategic Role of Biomarkers in Drug Discovery and Clinical Trials Every decision in drug development carries weight. The ...

HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype ...

The company reiterated that the ASPEN-Breast Phase II trial is "on track to dose its first patient this quarter," with interim data expected in Q3 2026. ALX2004 initial safety data is expected in the ...

Urothelial tumours represent the 6th most frequent cancer in men and its incidence continues to rise in both sexes. Fortunately, approximately 75% of ...

Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of advanced prostate cancer, including homologous recombination repair (HRR) gene alterations. Identifying the ...

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs Seoul, South Korea, December 16, ...

The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...